This is the authors' abstract. We don't add key points for this paper.
CAR T cells with a transgenic 'payload', so-called TRUCK T cells or the 'fourth-generation' CAR T cells, are worthwhile to explore to shape the tumor environment by the inducible release of transgenic immune modifiers. Such TRUCK T cells are moreover envisioned to be applied in fields beyond cancer therapy including the therapy of virus infections, auto-immune diseases or metabolic disorders.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chmielewski et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: